Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Flow cytometry [2]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-25495 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- STEAP2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 400 μL
- Concentration
- 2 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Comprehensive palmitoyl-proteomic analysis identifies distinct protein signatures for large and small cancer-derived extracellular vesicles.
Mariscal J, Vagner T, Kim M, Zhou B, Chin A, Zandian M, Freeman MR, You S, Zijlstra A, Yang W, Di Vizio D
Journal of extracellular vesicles 2020 Jun 10;9(1):1764192
Journal of extracellular vesicles 2020 Jun 10;9(1):1764192
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of STEAP2 in formalin fixed and paraffin embedded human prostate carcinoma. Samples were incubated with STEAP2 polyclonal antibody (Product # PA5-25495) followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of this antibody for immunohistochemistry. Clinical relevance has not been evaluated.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of 293 cells using a STEA2 polyclonal antibody (Product # PA5-25495) (right) compared to a negative control cell (left) at a dilution of 1:10-50, followed by a FITC-conjugated goat anti-rabbit antibody
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry of STEAP2 in 293 cells (right histogram). Samples were incubated with STEAP2 polyclonal antibody (Product # PA5-25495) followed by FITC-conjugated goat-anti-rabbit secondary antibody. Negative control cell (left histogram).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6. Prostate cancer-specific proteins are enriched in EVs. (a-c) Representative immunoblot of STEAP1 (a), STEAP2 (b) and ABCC4 (c) in EVs and WCL from PC3 and DU145 DIAPH3-KD cells along with the control proteins HSPA5 (L-EV enriched protein), CD9 (S-EV enriched protein) and Cav-1 (general EV protein). Bar plots represent the densitometric quantification across several blots. (d-f) FACS analysis ofSTEAP1 (d), STEAP2 (e) and ABCC4 (f) expression in cells and L-EVs from PC3 and DU145 DIAPH3-KD cells.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 7. Inhibition of palmitoylation reduces the abundance of prostate cancer-specific palmitoyl-proteins in EVs. (a-c) Representative immunoblot of the abundance of STEAP1 (A), STEAP2 (B) and ABCC4 (C) along with the control proteins HSPA5 (L-EV enriched protein), CD9 (S-EV enriched protein) and Cav-1 (general EV protein) in PC3 L- and S-EVs after inhibition of palmitoylation with 10 uM 2-BP for 24 h. Bar plots represent the densitometric quantification across replicate blots. (d) TRPS quantification of PC3 L- and S-EVs after inhibition of palmitoylation. (e) Yield of purified EV-protein from PC3 cells treated with or without 2-BP.
